Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Jasper Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
JSPR
Nasdaq
2834
https://www.jaspertherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Jasper Therapeutics Inc
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 8:30 pm
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- Mar 21st, 2024 8:30 pm
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
- Mar 19th, 2024 12:00 pm
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
- Mar 15th, 2024 12:00 pm
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
- Mar 4th, 2024 12:30 pm
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
- Feb 26th, 2024 9:30 pm
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
- Feb 23rd, 2024 1:00 pm
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
- Feb 7th, 2024 1:00 pm
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
- Feb 6th, 2024 1:59 pm
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
- Feb 5th, 2024 1:00 pm
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 2nd, 2024 1:00 pm
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
- Jan 5th, 2024 1:30 pm
Jasper Therapeutics, Inc. Announces Reverse Stock Split
- Jan 2nd, 2024 1:00 pm
Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
- Dec 10th, 2023 4:00 pm
Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
- Nov 30th, 2023 1:00 pm
Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress
- Nov 9th, 2023 2:48 pm
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 9th, 2023 1:00 pm
Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences
- Nov 8th, 2023 9:30 pm
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023
- Nov 2nd, 2023 1:00 pm
Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors
- Nov 1st, 2023 12:00 pm
Scroll